Enany, G. E., N. Nagui, H. Nada, M. R. E. Abdel-Halim, I. Sany, A. Nada, O. El-Ghannam, and M. Korany, "Bullous mastocytosis, a case report", JEWDS, vol. 21, issue 2, pp. 163-165, 2024.
El-Enany, G., M. El-Mofty, M. R. E. Abdel-Halim, D. Dermpath, N. Nagui, H. Nada, M. A. Saleh, I. Sany, A. Nada, O. El-Ghanam, et al., "Postpartum Castleman disease presenting as paraneoplastic pemphigus: a case report.", International journal of dermatology, vol. 62, issue 3, pp. e111-e113, 2023.
Pioltelli, P., P. T. Atkinson, M. Mattar, A. Edrees, H. M. A. Ahmad, A. Laymouna, M. R. E. Abdel-Halim, and G. Ragab, Monoclonal gammopathies with miscellaneous associations, , 2022.
Azzazi, Y., H. Khedr, and M. R. E. Abdel-Halim, "Pigmented colloid milium in a beta-thalassemia major patient: a case report.", International journal of dermatology, vol. 62, issue 12, pp. e626-e628, 2023.
Abdalla, D., M. Bosseila, M. R. E. Abdel-Halim, and I. Sany, "Peripilar Sign in Androgenetic Alopecia: Does It Really Indicate Peripilar Infiltrate?", Dermatology practical & conceptual, vol. 14, issue 1, 2024. Abstract

INTRODUCTION: Peripilar sign (PPS) is a trichoscopic sign that was first described in androgenetic alopecia (AGA) and is thought to reflect the presence of perifollicular infiltrate (PFI) in histopathology.

OBJECTIVES: To study PPS in a cohort of patients with AGA and to assess its validity as a sign indicative of PFI.

METHODS: One hundred patients with AGA (confirmed by trichoscopic examination) were recruited in this cross-sectional study. From those patients, frontal scalp biopsy was done for two subgroups, 22 patients with PPS and 23 patients without PPS. Both groups were compared as regards the presence of PFI.

RESULTS: Peripilar sign was present in 50% of the 100 studied cases. No significant difference existed between those with and those without PPS as regards PFI. Peripilar sign was significantly more encountered in patients with skin type III (p=0.001). Its absence was significantly associated with lower interpretability of yellow dots (p<0.001) and their scores were significantly positively correlated (r=0.498, p<0.001). Peripilar sign was significantly associated with absent melanophages histopathologically (p=0.011).

CONCLUSION: Peripilar sign as a trichoscopic sign in AGA does not reflect PFI. It represents a dark color more encountered in patients with lighter skin types. This can be explained by the increased contrast between the dark PPS and the lighter surrounding skin in lighter skin types. Further studies using melanocyte markers and Masson Fontana's stain are needed to further verify the cause of this peri-follicular dark color.

Elbendary, A., R. Youssef, M. R. E. Abdel-Halim, D. abd el halim, D. A. El Sharkawy, M. Alfishawy, M. A. Gad, A. A. Gad, and M. F. Elmasry, "Role of streptococcal infection in the etiopathogenesis of pityriasis lichenoides chronica and the therapeutic efficacy of azithromycin: a randomized controlled trial.", Archives of dermatological research, 2022. Abstract

The exact aetiology of pityriasis lichenoides chronica (PLC) remains unknown. While phototherapy is the most investigated therapeutic modality, azithromycin has been used scarcely. The aim of this study is to evaluate the therapeutic efficacy of azithromycin in the treatment of PLC compared to NB-UVB and evaluating the presence of streptococcal infection as a possible etiological factor in PLC patients. The study was designed as a randomised controlled trial. Twenty-four patients with PLC were randomly allocated into either azithromycin (n = 13, standard dose every 10 days) or NB-UVB (n = 11, thrice weekly) groups. End of study (EOS) was either complete clearance of lesions or a maximum of 8 weeks. Therapeutic efficacy was defined as percent reduction in lesions and was calculated for the rash as a whole, erythematous papules alone, and hypopigmented lesions alone and graded into complete, very-good, good, poor or no response. Anti-streptolysin O titre (ASOT), anti-deoxyribonuclease B titre (anti-DNaseB) and throat culture were evaluated at day 0. No significant difference existed between both groups as regards therapeutic efficacy. At EOS, NB-UVB achieved significantly more percent reduction in the extent of hypopigmented lesions and consequently in the rash as a whole (p = 0.001, p = 0.034, respectively). The extent of the rash as a whole was significantly less in the NB-UVB at EOS (p = 0.029, respectively). The effect of NB-UVB on hypopigmented lesions appeared early at week 4 of treatment. Only two patients, one from each group, relapsed during the 3 month follow-up. Evidence of recent streptococcal infection was present in 79% of the cases, mainly in the form of elevated ASOT (94.7%). It was significantly more encountered in young children (< 13 years) (p = 0.03) and was associated with more extent of erythematous papules and consequently with more extent of the rash as a whole (p = 0.05 and p = 0.01, respectively). It did not affect outcome of therapy at EOS. Azithromycin did not show more favorable response in patients with recent streptococcal infection. Therapeutic efficacy of azithromycin is comparable to NB-UVB in treatment of PLC; however, NB-UVB is superior in management of hypopigmented lesions. It is highly suggested that PLC could be a post streptococcal immune mediated disorder.Registration number: ClinicalTrials.gov, NCT03831269.

Abdelkader, H. A., M. M. Fawzy, N. Nour, and M. R. E. Abdel-Halim, "Eczematous mucinous eccrine nevus: a novel presentation with Meyerson phenomenon.", International journal of dermatology, 2022.
El-Komy, M. H. M., N. Shawky, A. Mourad, and M. R. Abdel-Halim, "Erythema gyratum repens-like psoriasis: a case report and review of literature.", International journal of dermatology, 2022.
Abdel-Halim, M. R. E., A. Mahmoud, and G. Ragab, "Cutaneous manifestations of ANCA associated vasculitis", Vessel Plus, vol. 6, 2022.
El-Komy, M. H. M., Y. Azzazi, R. El Naggar, and M. R. E. Abdel-Halim, "Chronic Atrophic Scar-like Plaque: Challenge.", The American Journal of dermatopathology, vol. 44, issue 1, pp. e6-e7, 2022.
Tourism